GLP1R and type 2 diabetes mellitus: The CV and kidney protective effects of the GLP-1 RAs and the SGLT2 inhibitors in particular has significantly changed the management of patients with T2D, who are at increased risk for adverse CV and kidney outcomes (13–16).